PRAP1

PRAP1 is an intrinsically disordered ~17 kDa protein that functions as a stress-protective and lipid-handling factor across epithelial and cancer contexts (PMID:32629119, PMID:33168624). In the endoplasmic reticulum it acts as a lipid-binding cofactor, directly binding triglyceride and forming a ternary complex with MTTP that is required to facilitate MTTP-mediated lipid transport and apoB-containing lipoprotein assembly and secretion; the E85V mutation abolishes ternary complex formation and impairs this activity (PMID:33168624). PRAP1 is a direct transcriptional target of p53, with functional p53-response elements in its first intron, and upon DNA damage it promotes cell-cycle arrest and protects cells from apoptosis (PMID:23235459). Consistent with a cytoprotective role, PRAP1 is highly expressed in small intestinal epithelium, where its loss increases apoptosis and p21 expression after total-body irradiation (PMID:32629119). In cancer cells it exerts dual roles: it physically interacts with the spindle-assembly checkpoint protein MAD1 and, when overexpressed, impairs the mitotic checkpoint and down-regulates MAD1 protein, producing chromosomal instability (PMID:24374861); and in colorectal cancer it promotes proliferation and suppresses ferroptosis through activation of Nrf2 signaling (PMID:40373840). PRAP1 expression is itself controlled upstream by ARID1A and progesterone receptor in the uterine epithelium (PMID:31660454).

1. 2012 Medium

   Established the transcriptional control and pro-survival function of PRAP1 by showing it is a direct p53 target that limits apoptosis after DNA damage, answering how PRAP1 is induced and what it does under genotoxic stress.

   Evidence ChIP of p53 at PRAP1 intron 1, siRNA knockdown with apoptosis/viability assays after 5-FU and irradiation

   PMID:23235459

   Open questions at the time

   • Mechanism by which PRAP1 protein blocks apoptosis is not defined
   • Single-lab functional data
   • Downstream effectors of PRAP1-induced arrest unknown
2. 2014 Medium

   Identified a physical PRAP1–MAD1 interaction and linked PRAP1 overexpression to mitotic checkpoint failure and chromosomal instability, connecting PRAP1 to genome stability control.

   Evidence Yeast two-hybrid screen, reciprocal co-immunoprecipitation, mitotic checkpoint and chromosome analysis in HCC cells with stable PRAP1 overexpression

   PMID:24374861

   Open questions at the time

   • Whether interaction is direct in vitro not shown
   • Mechanism of MAD1 down-regulation (degradation vs transcription) undefined
   • Single cell-type context
3. 2018 Low

   Proposed a role for PRAP1 in DNA-damage repair by showing knockdown elevates γH2AX under chronic cisplatin exposure, extending its stress-protective role to endothelial cells.

   Evidence siRNA knockdown, γH2AX immunostaining and microarray expression profiling in microvascular endothelial cells

   PMID:29886035

   Open questions at the time

   • Pathway partners (YWHAB, MDM2, ISG15, LYN, CUL1) inferred from expression, not direct interaction
   • Single knockdown method with one functional readout
   • No mechanistic link to repair machinery
4. 2019 Medium

   Defined upstream regulation of PRAP1, showing that progesterone suppresses uterine PRAP1 in an ARID1A- and PGR-dependent manner, placing PRAP1 within hormonal/chromatin-remodeling control.

   Evidence Uterus-specific Arid1a knockout and PGR knockout mice with ovariectomy/progesterone challenge, RT-qPCR and IHC

   PMID:31660454

   Open questions at the time

   • Direct vs indirect regulation of the PRAP1 locus not resolved
   • Functional consequence of uterine PRAP1 regulation unknown
5. 2020 High

   Resolved a molecular biochemical function for PRAP1 as an ER lipid-binding cofactor that forms a TG–MTTP ternary complex required for lipoprotein secretion, the most mechanistically defined PRAP1 activity.

   Evidence In vitro lipid binding, E85V mutagenesis with functional rescue/loss, lipoprotein secretion assays, Prap1-/- and E85V knock-in mouse models

   PMID:33168624

   Open questions at the time

   • Structural basis of TG/MTTP binding not determined
   • Relationship between lipid-binding role and cytoprotective/cancer roles unexplored
6. 2020 Medium

   Demonstrated an in vivo cytoprotective role in the gastrointestinal barrier, with PRAP1 loss increasing irradiation-induced apoptosis and p21 in intestinal epithelium.

   Evidence Recombinant protein characterization, Prap1-/- mice with total-body irradiation, apoptosis/p21 readouts, intestinal enteroids

   PMID:32629119

   Open questions at the time

   • Molecular pathway connecting PRAP1 to apoptosis suppression in vivo undefined
   • Relation to its p53-target status not tested directly
7. 2025 Medium

   Extended PRAP1's pro-survival function to cancer by showing it promotes colorectal cancer proliferation and suppresses ferroptosis via Nrf2 pathway activation.

   Evidence Overexpression/knockdown, proliferation/apoptosis assays, iron and Prussian blue staining, Nrf2 pathway Western blots, nude mouse xenografts

   PMID:40373840

   Open questions at the time

   • Direct molecular link between PRAP1 and Nrf2 activation not established
   • Whether ferroptosis suppression depends on lipid-binding activity unknown

• How PRAP1's defined ER lipid-binding/MTTP cofactor activity mechanistically connects to its diverse cytoprotective, mitotic-checkpoint, and Nrf2/ferroptosis roles remains unresolved.
• No structural model unifying the disordered protein's multiple activities
• No direct biochemical link from PRAP1 to Nrf2 or to apoptosis machinery
• Tissue-specific function determinants unknown